Tag: Flibanserin

New research investigates the financial conflicts of interest (FCOI) of patient advocacy organizations (PAOs) in the United States.

From STAT: It “looks like the FDA is using this guidance to keep another company from trying to get a female sexual desire drug approved...

A group of researchers in Denmark examines what existing animal studies can tell us about the sexual side-effects of SSRI antidepressants.

The drug watch blog Evidencer.org takes on Flibanserin (Addyi) the first drug claiming “to enhance women’s sexual drive…” Article →

“A STAT examination of hundreds of social media accounts maintained by health-care professionals finds that while they often tweet medical advice, they almost never disclose potential conflicts of...

Pharmaguy covers a study published in JAMA this month which found that Addyi, the new drug approved by the FDA to treat low sexual...

“The Food and Drug Administration’s approval of pharmaceutical treatment for low sexual desire in women has launched a heated debate over the dangers and benefits of medicalizing sex,” Maya Dusenbery writes in the Pacific Standard. Is “female Viagra” a feminist victory or a product of clever faux-feminist marketing by Big Pharma?

“The National Women’s Health Network launched the 'Pass on the Pink Pill – Or Pass Out' campaign, to warn women of the marginal benefits...

Ed Silverman reports that only 80 prescriptions for Addyi, or Flibanserin, were filled in the drugs’ first two weeks on the market. Article →

Despite concerns about the drug’s necessity, effectiveness, and side-effects, Flibanserin (Addyi) has come to market as the first drug designed to increase sexual desire in women

In the September issue of The Journal of the American Medical Association (JAMA) three FDA advisory committee members describe the convergence of factors that made the committee’s recommendation to approve flibanserin especially challenging and politically charged.

CBC News Canada voices sex therapists and psychiatrists concerns over the FDAs decision to approve Flibanserin last week. Critics contend, “it's an ineffectual pharmacological solution for a problem better treated with relationship counselling, sex therapy and behavioural changes.” Walid Gellad, the co-director of the Center for Pharmaceutical Policy and Prescribing adds, “"[I] believe that it should be used by almost no one.”

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Flibanserin (Addyi) to treat low sexual desire in women despite concerns about the drug's limited efficacy and doubts over its clinical relevance. That the drug is being called the "pink Viagra" can be misleading as Viagra treats erectile dysfunction by improving blood flow while Flibanserin targets the brain, and must be taken daily.